Prasugrel reduces ischaemic infarct volume and ameliorates neurological deficits in a non-human primate model of middle cerebral artery thrombosisAtsuyuki Tomizawa, Atsuhiro Sugidachi, Kousaku Ohno et al.|Thrombosis Research|2015Cited by 17
Selective Blockade of P2Y12 Receptors by Prasugrel Inhibits Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion in RatsAtsuhiro Sugidachi, Y. Niitsu, Masami Hashimoto et al.|Journal of Cardiovascular Pharmacology|2011Cited by 15
The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic strokeAtsuhiro Sugidachi, Atsuyuki Tomizawa, Kousaku Ohno et al.|European Journal of Pharmacology|2016Cited by 14
Prasugrel, a Platelet P2Y <sub>12</sub> Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb IschemiaKousaku Ohno, Atsuhiro Sugidachi, Atsuyuki Tomizawa et al.|Journal of the American Heart Association|2016Cited by 11
Comparison of antiplatelet effects of prasugrel and ticagrelor in cynomolgus monkeys by an ELISA-based VASP phosphorylation assay and platelet aggregationAtsuyuki Tomizawa, Atsuhiro Sugidachi, Kousaku Ohno et al.|Thrombosis and Haemostasis|2013Cited by 11